IL212066A - 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment - Google Patents

4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment

Info

Publication number
IL212066A
IL212066A IL212066A IL21206611A IL212066A IL 212066 A IL212066 A IL 212066A IL 212066 A IL212066 A IL 212066A IL 21206611 A IL21206611 A IL 21206611A IL 212066 A IL212066 A IL 212066A
Authority
IL
Israel
Prior art keywords
compositions
selection
processes
production
cxcr4 antibodies
Prior art date
Application number
IL212066A
Other languages
English (en)
Hebrew (he)
Other versions
IL212066A0 (en
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of IL212066A0 publication Critical patent/IL212066A0/en
Publication of IL212066A publication Critical patent/IL212066A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
IL212066A 2008-10-01 2011-03-31 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment IL212066A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (en) 2008-10-01 2008-10-01 Novel anti CXCR4 antibodies and their use for the treatment of cancer
US17374309P 2009-04-29 2009-04-29
PCT/EP2009/062787 WO2010037831A1 (en) 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer

Publications (2)

Publication Number Publication Date
IL212066A0 IL212066A0 (en) 2011-06-30
IL212066A true IL212066A (en) 2015-05-31

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212066A IL212066A (en) 2008-10-01 2011-03-31 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment

Country Status (28)

Country Link
US (4) US8557964B2 (cg-RX-API-DMAC7.html)
EP (2) EP2172485A1 (cg-RX-API-DMAC7.html)
JP (1) JP5723279B2 (cg-RX-API-DMAC7.html)
KR (1) KR101671039B1 (cg-RX-API-DMAC7.html)
CN (1) CN102209730B (cg-RX-API-DMAC7.html)
AR (1) AR073748A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009299787B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0920531A2 (cg-RX-API-DMAC7.html)
CA (1) CA2738782C (cg-RX-API-DMAC7.html)
CL (1) CL2011000730A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115572T1 (cg-RX-API-DMAC7.html)
DK (1) DK2342233T3 (cg-RX-API-DMAC7.html)
ES (1) ES2503732T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20146084B (cg-RX-API-DMAC7.html)
HR (1) HRP20140899T1 (cg-RX-API-DMAC7.html)
IL (1) IL212066A (cg-RX-API-DMAC7.html)
MA (1) MA32928B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011003509A (cg-RX-API-DMAC7.html)
NZ (1) NZ592363A (cg-RX-API-DMAC7.html)
PL (1) PL2342233T3 (cg-RX-API-DMAC7.html)
PT (1) PT2342233E (cg-RX-API-DMAC7.html)
RS (1) RS53578B1 (cg-RX-API-DMAC7.html)
RU (1) RU2573897C2 (cg-RX-API-DMAC7.html)
SI (1) SI2342233T1 (cg-RX-API-DMAC7.html)
TW (1) TWI469792B (cg-RX-API-DMAC7.html)
UA (1) UA102867C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010037831A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102969B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
JP2014504147A (ja) * 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン Ｈｉｖの治療用抗体
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
JP6506280B2 (ja) * 2013-08-02 2019-05-08 ファイザー・インク 抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート
JP2016530895A (ja) 2013-09-23 2016-10-06 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 動物細胞を遺伝子改変する改良された方法
AR104413A1 (es) * 2015-04-27 2017-07-19 Pf Medicament Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
EP3408378B1 (en) 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
JPWO2017203799A1 (ja) * 2016-05-25 2019-02-28 株式会社東芝 エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3052070A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
US20230181635A1 (en) 2018-03-13 2023-06-15 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
WO2025049591A1 (en) * 2023-08-28 2025-03-06 Regeneron Pharmaceuticals, Inc. Anti-cxcr4 antibodies and uses thereof
CN117003876B (zh) * 2023-08-31 2024-06-18 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2006086883A1 (en) * 2005-02-16 2006-08-24 Universite De Montreal Biosensors for monitoring receptor-mediated g-protein activation
EP1871807B1 (en) * 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
CA2724409A1 (en) * 2008-05-14 2009-11-19 Eli Lilly And Company Anti-cxcr4 antibodies

Also Published As

Publication number Publication date
AU2009299787A2 (en) 2011-06-02
ZA201102969B (en) 2011-12-28
JP2012504401A (ja) 2012-02-23
EP2342233B1 (en) 2014-06-25
UA102867C2 (uk) 2013-08-27
WO2010037831A1 (en) 2010-04-08
US20110287451A1 (en) 2011-11-24
CL2011000730A1 (es) 2012-02-03
CA2738782A1 (en) 2010-04-08
CN102209730B (zh) 2014-11-05
CA2738782C (en) 2017-11-28
AR073748A1 (es) 2010-12-01
EP2172485A1 (en) 2010-04-07
RS53578B1 (sr) 2015-02-27
DK2342233T3 (da) 2014-09-29
BRPI0920531A2 (pt) 2021-02-23
PL2342233T3 (pl) 2014-11-28
MX2011003509A (es) 2011-05-02
SI2342233T1 (sl) 2014-10-30
PT2342233E (pt) 2014-10-03
HRP20140899T1 (hr) 2014-11-07
US20140050661A1 (en) 2014-02-20
RU2573897C2 (ru) 2016-01-27
CN102209730A (zh) 2011-10-05
US20110020218A1 (en) 2011-01-27
TW201018483A (en) 2010-05-16
TWI469792B (zh) 2015-01-21
AU2009299787A1 (en) 2010-04-08
EP2342233A1 (en) 2011-07-13
AU2009299787B2 (en) 2015-06-18
KR20110081229A (ko) 2011-07-13
NZ592363A (en) 2012-08-31
RU2011115559A (ru) 2012-11-10
IL212066A0 (en) 2011-06-30
JP5723279B2 (ja) 2015-05-27
US8557964B2 (en) 2013-10-15
CY1115572T1 (el) 2017-01-04
HK1163119A1 (en) 2012-09-07
US9388248B2 (en) 2016-07-12
KR101671039B1 (ko) 2016-11-01
MA32928B1 (fr) 2012-01-02
GEP20146084B (en) 2014-05-13
ES2503732T3 (es) 2014-10-07
US20110294156A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
IL212066A (en) 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment
IL273607A (en) Humanized antibodies against liv-1, preparations containing them and their uses
IL287311A (en) Antibodies and processes for their preparation
IL252561B (en) Antibodies against Siglac-15 polynucleotides encoding them, preparations containing them and their uses
IL245050A0 (en) Optimum fc variants, pharmaceutical preparations and drugs containing them, and a method for their preparation
IL205222A (en) Nanoparticles that include iron, a method of making them, a pharmaceutical composition that includes them and uses them
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
IL216826A0 (en) Pyridil-triazine derivatives, compositions comprising the same and processes for producing the same
IL226383B (en) Antibodies against ccl20, preparations containing them and their uses
EP2307494A4 (en) PROTEIN AND STARCH COMPOSITIONS, METHODS OF MAKING THE SAME, AND USES THEREOF
ZA201203183B (en) Sulfomethylsuccinates, process for making same and compositions containing same
PL2588556T3 (pl) Kompozycja na bazie 2,3,3,3-tetrafluoropropenu
IL212099A0 (en) Cross-species specific psmaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
SI3581631T1 (sl) Sestavki, ki obsegajo 2,3,3,3-tetrafluoropropen
ZA201102081B (en) Engineered anti0il-13 antibodies,compositions,methods and uses
IL211441A (en) Variety of endolysin, methods of manufacture and use thereof
WO2011075636A3 (en) Wise binding agents and epitopes
IL226023A0 (en) Antibodies against 5dr, preparations containing them and their uses
EP2282735A4 (en) COMPOUNDS, COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
MY150063A (en) Coated comestibles and processes for their preparation
IL205073A (en) 2 bst antibodies, methods of making them, medicinal preparations containing them and their use
EP2291450A4 (en) POLYMERIC COMPOSITIONS, METHOD FOR THE PRODUCTION THEREOF AND ARTICLES PRODUCED THEREFROM
ZA201206055B (en) Antibodies against cxcr4
IL219470A (en) Antibacterial antibody, preparations containing it and its uses
IL216865A0 (en) Aptamer for chymase, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees